Johnson & Johnson has announced that it has entered into a definitive agreement to acquire V-Wave, a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of US$600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately US$1.1 billion. V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech.
The planned acquisition of V-Wave will extend Johnson & Johnson MedTech’s position as an innovation leader in addressing cardiovascular disease. It will further accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists.
Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said: “We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease. We recognise the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs.”